Results for: Phase 2b Trial

Vera Therapeutics has released promising long-term data from its ORIGIN Phase 2b trial, showing that atacicept, a B-cell modulator, can effectively stabilize kidney function in patients with immunoglobulin A nephropathy (IgAN). This suggests a potential for preventing kidney failure in these individuals. The data, presented at the American Society of Nephrology Kidney Week 2024 and published in the Journal of the American Society of Nephrology, highlight atacicept’s disease-modifying capabilities and pave the way for a potential best-in-class treatment option for IgAN.

Alto Neuroscience, Inc. (ANRO) announced disappointing results from its Phase 2b trial of ALTO-100 for major depressive disorder (MDD), leading to a significant drop in the company’s stock price. Despite the setback, Alto remains optimistic about its biomarker-driven approach and its other ongoing clinical trials.